Navigation Links
Pharmion to Present Clinical Data on Commercial and Pipeline,Products at 2007 American Society of Clinical Oncology (ASCO),Meeting

Data on six products from Pharmion's pipeline provide support for epigenetic and combination therapies, including promising Phase III data on use of Thalidomide to treat multiple myeloma

BOULDER, Colo., May 31, 2007 /PRNewswire-FirstCall/ -- Pharmion Corporation reported today that data from 18 abstracts of studies investigating the company's marketed and pipeline products will be presented or published at the American Society of Clinical Oncology's (ASCO) 43rd Annual Meeting in Chicago (June 1-5, 2007). These abstracts include summaries of data from studies of each of the six key products in the company's commercial and development portfolio, for multiple indications, including Myelodysplastic Syndromes (MDS), multiple myeloma, Hodgkin's lymphoma, small cell lung cancer and advanced hormone-refractory prostate cancer.

"ASCO 2007 provides further evidence of Pharmion's progress," said Patrick J. Mahaffy, president and chief executive officer of Pharmion. "Data from six of our products will be presented or published, including Phase III data for Satraplatin and Thalidomide, encouraging Phase II data for Amrubicin, Vidaza and MGCD0103, and human bioavailability data for oral azacitidine. These data demonstrate the strength of the Pharmion business model; we are focused solely on oncology, we have multiple compounds demonstrating clinical benefit, and we have a U.S. and international infrastructure to support those products. Pharmion is well-positioned to take full advantage of the strong portfolio of products in our pipeline."

"The data at ASCO affirm Pharmion's leadership in developing epigenetic therapies as a promising approach to treating cancer," said Andrew R. Allen, Pharmion's chief medical officer. "MGCD0103, our class-selective HDAC inhibitor, is showing meaningful activity as monotherapy in advanced Hodgkin's lymphoma. Furthermore, as we begin to understand the way in which multiple epigen
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Pharmions Amrubicin Shows Encouraging Results Compared to Standard of Care in Second Line Treatment of Small Cell Lung Cancer
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference
Post Your Comments:
(Date:8/4/2015)... BEIJING , Aug. 4, 2015 Concord Medical ... a leading specialty hospital management solution provider and operator of ... China , today announced it will release ... the market closes on August 17, 2015. Management ... following day, at 8:00 a.m. EDT on August 18, 2015 ...
(Date:8/4/2015)... SAN DIEGO , Aug. 4, 2015 /PRNewswire/ ... a three-dimensional biology company focused on delivering scientific ... announced that the Company has hired Paul ... in vitro tissue service and product business. Mr. Gallant ... R&D experience in the drug discovery industry, most ...
(Date:8/4/2015)... 4, 2015  ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, today ... will present live at VirtualInvestorConferences.com on August 6, ... TIME: 12:15PM EDT LINK: http://tinyurl.com/aug6-pre-ctrv ... online event where investors are invited to ask ...
Breaking Medicine Technology:Concord Medical to Report Second Quarter 2015 Financial Results on August 17, 2015 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 2Organovo Holdings, Inc. Appoints Paul Gallant as General Manager 3ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 2ContraVir to Webcast Investor Presentation on August 6: VirtualInvestorConferences.com 3
... , May 10 Ferring Pharmaceuticals ... Women,s Health product portfolio with the acquisition of ... acid), a first-in-class, non-hormonal therapy indicated specifically for ... (HMB).  The company will initially market LYSTEDA in ...
... 10 Ampio Pharmaceuticals, Inc. (OTC Bulletin Board: AMPE), today announced the ... Mr. Macaluso replaces Dr. David Bar-Or, who remains the Chief Scientific Officer and ... Bar-Or have served on Ampio,s Board since the date of its acquisition of ... , , ...
Cached Medicine Technology:Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 2Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 3Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 4Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc. 5Ampio Pharmaceuticals, Inc. Appoints New Chairman and Chief Financial Officer 2
(Date:8/4/2015)... ... 04, 2015 , ... assistPoint Partners, LLC is proud ... patient assistance programs. Through a secure web portal, assistPoint connects Life Sciences, Patients ... level, cloud-based application and workflow solution. This provides cancer center patient advocates, financial ...
(Date:8/4/2015)... FL (PRWEB) , ... August 04, 2015 , ... ... testing organization which provides vascular, electrocardiogram (EKG), echocardiogram, and NCV testing, announced their ... has been successfully identifying previously undiagnosed cardiovascular abnormalities one program at a time. ...
(Date:8/4/2015)... ... August 04, 2015 , ... Bayco Products, Inc. announces ... to fit, for example, on hard hats that have a flip-up face shield. The ... allows users to work without having to remove their headlamp when raising or lowering ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... Worldwide Power Products is expanding its reach in Texas. Effective July 1st of ... Systems North Texas generator division. With the North Texas acquisition, Worldwide Power ...
(Date:8/4/2015)... , ... August 04, 2015 , ... One of the ... to discuss his new book, The Pain Antidote , which provides strategies for ... Las Vegas Recovery Center’s Chronic Pain Treatment Program, wrote the book in conjunction with ...
Breaking Medicine News(10 mins):Health News:assistPoint.com Web Site Launched 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 2Health News:Colleges and High Schools Across the Country Are Joining the Wimbledon U Team Uncovering Unknown Cardiac Conditions and Promoting Heart Healthy Athletes 3Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 2Health News:New Nightstick® NSP-4614B Dual-LightTM Headlamp fits more functionality into more places 3Health News:North Texas Acquisition Press Release 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 2Health News:Medical Expert's New Book Offers Help for Chronic Pain Sufferers 3
... hospitals , , MONDAY, Dec. 17 (HealthDay News) -- A ... and anxiety that often follows major surgery, new research ... was equivalent to a [dose] of morphine, which was ... Hinshaw, professor of surgery and a member of the ...
... NEW MARTINSVILLE, W.Va., Dec. 17 In ... become tomorrow,s environmental,stewards, Bayer Corporation and the ... (UNEP RONA) today announced a new World,Environment ... Competition in Bayer MaterialScience New Martinsville partner,schools., ...
... OWINGS MILLS, Md., Dec. 17 Medifast, Inc.,(NYSE: ... has received approval to sell,Medifast Weight Control Centers ... available in 43 states. Medifast recently,received approval to ... Rhode Island and Virginia., "The Medifast Weight ...
... season is a,great opportunity to relax, spend time with family, ... the next 12 months. These top resolutions,offered by the American ... healthy new you in 2008., "Creating and sticking to ... you can give yourself this holiday season," said AMA,President, Ron ...
... a high volume of corrective surgeries show higher survival ... -- Babies with congenital heart defects are more likely ... the most experience in treating such cases, U.S. researchers ... figures from the 2003 Kids, Inpatient Database, which is ...
... Murtha, Chairman of the House Appropriations Subcommittee on Defense, this ... veterans blinded by war and for research to restore their ... gives the Man of Vision Award to an individual who ... of the challenges of vision loss. Among previous awardees have ...
Cached Medicine News:Health News:Massage Eases Pain, Anxiety After Surgery 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools 2Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools 3Health News:New Bayer, United Nations Partnership Brings International Environment and Art Competition to Local Elementary and Middle Schools 4Health News:Medifast, Inc. Receives Approval to Sell Medifast Weight Control Centers Franchises in Seven Additional States 2Health News:AMA: Resolutions for a Healthy New You in the New Year 2Health News:Babies With Heart Defects Do Best at Hospitals With Most Experience 2Health News:Champion of blinded soldiers, Congressman Murtha, is Man of Vision 2
... Sutureless Mitek ConTack Labral Anchor is ... washer used for soft tissue reattachment ... adjusts to the bony contour of ... anchor uses Radial Osteo Compression (ROC) ...
... Suture Anchors just got better. How can ... do that? Simply by becoming more convenient ... mini-open, and arthroscopic. The TwinFix Suture Anchor ... with a unique, convenient and timesaving anchor ...
... EZ fasteners are polyethylene ... tissue reattachment to bone. ... radial osteo compression (ROC) ... strength. ROC EZ fasteners ...
The Knotless Anchor, a titanium alloy implant, is used for soft tissue reattachment to bone. The Knotless Anchor is indicated for open and arthroscopic Bankart repairs....
Medicine Products: